KRAS and colorectal carcinoma: Based on these results, adagrasib and cetuximab is compared to standard chemotherapy plus/minus antiangiogenic agent in the KRYSTAL-10 trial, a phase 3 randomized trial in patients with KRAS G12C mutated metastatic CRC who have progressed after first-line treatment (NCT04793958).